BME:ALMPharmaceuticals
Why Almirall (BME:ALM) Is Up 6.2% After Strong Four-Year Lebrikizumab Phase 3b Data
Almirall, S.A. recently reported positive long-term interim Phase 3b ADlong results for lebrikizumab in moderate-to-severe atopic dermatitis, showing sustained efficacy and a consistent safety profile over up to four years, at the American Academy of Dermatology meeting in Denver.
The data, including high rates of near-complete skin clearance and itch relief mostly achieved without topical corticosteroids, underline lebrikizumab’s potential to anchor Almirall’s European dermatology franchise...